BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 27738759)

  • 1. Comprehensive study of mutational and clinicopathologic characteristics of adenocarcinoma with lepidic pattern in surgical resected lung adenocarcinoma.
    Xu Y; Zhu C; Qian W; Zheng M
    J Cancer Res Clin Oncol; 2017 Jan; 143(1):181-186. PubMed ID: 27738759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
    Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
    Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
    Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
    Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.
    Wang R; Pan Y; Li C; Zhang H; Garfield D; Li Y; Ye T; Hu H; Luo X; Li H; Zhang Y; Zhang J; Zhou X; Shen L; Pao W; Sun Y; Chen H
    J Thorac Oncol; 2014 Jun; 9(6):760-8. PubMed ID: 24481316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
    Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
    Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.
    Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Fujimoto M; Kawakami F; Tsuruyama T; Travis WD; Date H; Haga H
    J Thorac Oncol; 2013 Jan; 8(1):52-61. PubMed ID: 23242438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of mutational and clinicopathologic characteristics of lung adenocarcinoma with clear cell component.
    Gu C; Pan X; Wang R; Li Y; Shen X; Shi J; Chen H
    Oncotarget; 2016 Apr; 7(17):24596-603. PubMed ID: 27013585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indications for sublobar resection of clinical stage IA radiologic pure-solid lung adenocarcinoma.
    Hattori A; Matsunaga T; Takamochi K; Oh S; Suzuki K
    J Thorac Cardiovasc Surg; 2017 Sep; 154(3):1100-1108. PubMed ID: 28629842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KIF5B-RET Fusion gene may coincide oncogenic mutations of EGFR or KRAS gene in lung adenocarcinomas.
    Kim JO; Lee J; Shin JY; Oh JE; Jung CK; Park JK; Sung SW; Bae SJ; Min HJ; Kim D; Park JY; Kang JH
    Diagn Pathol; 2015 Aug; 10():143. PubMed ID: 26268359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation.
    Kadota K; Yeh YC; D'Angelo SP; Moreira AL; Kuk D; Sima CS; Riely GJ; Arcila ME; Kris MG; Rusch VW; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2014 Aug; 38(8):1118-27. PubMed ID: 25029118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive evaluation of clinicopathologic characteristics, molecular features and prognosis in lung adenocarcinoma with solid component.
    Li J; You W; Zheng D; Yan B; Ma X; Pan Y; Zhang Y; Li Y; Shen X; Cheng X; Sun Y; Chen H
    J Cancer Res Clin Oncol; 2018 Apr; 144(4):725-734. PubMed ID: 29368062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma.
    Yip PY; Yu B; Cooper WA; Selinger CI; Ng CC; Kennedy CW; Kohonen-Corish MR; McCaughan BC; Trent RJ; Boyer MJ; Kench JG; Horvath LG; O'Toole SA
    J Thorac Oncol; 2013 Apr; 8(4):408-14. PubMed ID: 23392229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic characteristics and prognostic significance of EGFR and p53 mutations in surgically resected lung adenocarcinomas ≤2 cm in maximal dimension.
    Lin MW; Wu CT; Shih JY; Chang YL; Yang PC
    J Surg Oncol; 2014 Aug; 110(2):99-106. PubMed ID: 24788590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas.
    Sonobe M; Kobayashi M; Ishikawa M; Kikuchi R; Nakayama E; Takahashi T; Menju T; Takenaka K; Miyahara R; Huang CL; Okubo K; Bando T; Date H
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S347-54. PubMed ID: 21607772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.
    Sun PL; Seol H; Lee HJ; Yoo SB; Kim H; Xu X; Jheon S; Lee CT; Lee JS; Chung JH
    J Thorac Oncol; 2012 Feb; 7(2):323-30. PubMed ID: 22237264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lung adenocarcinoma: Sustained subtyping with immunohistochemistry and EGFR, HER2 and KRAS mutational status.
    Sousa V; Rodrigues C; Silva M; Alarcão AM; Carvalho L
    Rev Port Pneumol (2006); 2015; 21(3):113-25. PubMed ID: 25926253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland.
    Grosse A; Grosse C; Rechsteiner M; Soltermann A
    Diagn Pathol; 2019 Feb; 14(1):18. PubMed ID: 30744664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society.
    Villa C; Cagle PT; Johnson M; Patel JD; Yeldandi AV; Raj R; DeCamp MM; Raparia K
    Arch Pathol Lab Med; 2014 Oct; 138(10):1353-7. PubMed ID: 24571650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comprehensive investigation of molecular features and prognosis of lung adenocarcinoma with micropapillary component.
    Zhang Y; Wang R; Cai D; Li Y; Pan Y; Hu H; Wang L; Li H; Ye T; Luo X; Zhang Y; Li B; Shen L; Sun Y; Chen H
    J Thorac Oncol; 2014 Dec; 9(12):1772-8. PubMed ID: 25226429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.